Canadian scientists have discovered that a hidden gut bacteria molecule is secretly driving diabetes and liver disease, overturning decades of medical understanding about what really causes these devastating health conditions.
Story Highlights
- D-lactate from gut bacteria identified as major driver of high blood sugar and liver disease
- Revolutionary “gut trap” therapy successfully reversed metabolic dysfunction in mouse studies
- Breakthrough challenges traditional diabetes treatments that target hormones instead of root causes
- Human trials needed to validate this promising new approach to metabolic disease treatment
Hidden Bacterial Culprit Finally Exposed
Researchers at McMaster University have identified D-lactate, a molecule produced by gut bacteria, as a previously unknown trigger of high blood sugar and liver problems. Dr. Jonathan Schertzer’s team discovered that this bacterial byproduct travels from the gut into the bloodstream, where it forces the liver to overproduce both glucose and fat. The finding represents a fundamental shift from the traditional focus on L-lactate from muscles, revealing how our own gut bacteria may be sabotaging our metabolic health through mechanisms science completely missed.
The research published in Cell Metabolism demonstrates that D-lactate levels correlate directly with obesity and diabetes in both mice and humans. Unlike the well-known Cori cycle involving muscle-derived L-lactate, this bacterial D-lactate pathway operates independently and appears particularly active in obese individuals. The discovery explains why some people struggle with blood sugar control despite following conventional treatments that target insulin or liver function directly rather than addressing the underlying bacterial fuel source.
Revolutionary Gut Trap Therapy Shows Promise
Scientists developed an innovative biodegradable polymer “trap” that captures D-lactate in the gut before it enters the bloodstream. When tested in obese mice, this approach dramatically improved blood sugar control and reduced liver fat accumulation. The treatment works by intercepting the bacterial metabolite at its source, preventing it from reaching the liver where it triggers harmful glucose and fat production. This represents a completely new therapeutic strategy that addresses the root cause rather than managing symptoms.
The gut trap approach proved more effective than traditional diabetes medications because it stops the problem at its bacterial source. Obese mice treated with the D-lactate trap showed significant improvements in metabolic markers within weeks. Dr. Schertzer emphasized that this strategy represents “a completely new way to think about treating metabolic diseases like type 2 diabetes and fatty liver disease” by targeting microbial fuels rather than downstream hormonal pathways that current medications attempt to manipulate.
Implications for Future Treatment Approaches
This discovery could revolutionize how doctors treat the millions of Americans suffering from diabetes and fatty liver disease. Current treatments focus on managing insulin resistance or reducing glucose production through expensive medications with significant side effects. The new approach targets the bacterial source of the problem, potentially offering more effective treatment with fewer complications. However, human clinical trials are still needed to validate the safety and effectiveness of gut D-lactate trapping in people.
Gut substrate trap of D-lactate from microbiota improves blood glucose and fatty liver disease in obese micehttps://t.co/sV5D2Ssr84
Surprising gut discovery reveals a hidden trigger of diabetes and liver disease and opens up a fresh way to fight diabeteshttps://t.co/dD0qjdfe97— Reiner (@erlesen) September 12, 2025
The research opens new possibilities for personalized medicine based on individual gut bacteria profiles and D-lactate production levels. Future treatments might include targeted probiotics, dietary modifications, or refined versions of the gut trap technology specifically designed for human use. This breakthrough demonstrates how understanding the complex relationship between gut bacteria and human metabolism can lead to innovative solutions that address chronic diseases at their microbial roots rather than simply managing their downstream effects.
Sources:
High Blood Sugar and Liver Disease Fueled by D-Lactate
Scientists Discover a Surprising New Way To Fight Diabetes
Surprising gut discovery reveals a hidden trigger of diabetes and liver disease
Canadian scientists trap gut microbe fuel to improve blood sugar and liver health
